MEDICATION GUIDE
TECENTRIQ® (te-SEN-trik)
(atezolizumab)
injection

What is the most important information I should know about TECENTRIQ?
TECENTRIQ is a medicine that may treat a type of cancer in the bladder and urinary tract or a type of lung cancer by working with your immune system. TECENTRIQ can cause your immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.

Call or see your healthcare provider right away if you get any symptoms of the following problems or these symptoms get worse:

Lung problems (pneumonitis). Signs and symptoms of pneumonitis may include:
• new or worsening cough
• shortness of breath
• chest pain

Liver problems (hepatitis). Signs and symptoms of hepatitis may include:
• yellowing of your skin or the whites of your eyes
• severe nausea or vomiting
• pain on the right side of your stomach area (abdomen)
• drowsiness
• dark urine (tea colored)
• bleeding or bruising more easily than normal
• feeling less hungry than usual

Intestinal problems (colitis). Signs and symptoms of colitis may include:
• diarrhea (loose stools) or more bowel movements than usual
• blood or mucus in your stools or dark, tarry, sticky stools
• severe stomach area (abdomen) pain or tenderness
• dizziness or fainting
• feeling more hungry or thirsty than usual
• hair loss
• dark urine (tea colored)
• bleeding or bruising more easily than normal
• feeling less hungry than usual

Hormone gland problems (especially the thyroid, adrenal glands, pancreas, and pituitary). Signs and symptoms that your hormone glands are not working properly may include:
• headaches that will not go away or unusual headaches
• extreme tiredness
• weight gain or weight loss
• dizziness or fainting
• feeling more hungry or thirstier than usual
• weight gain or weight loss
• dizziness or fainting
• feeling more hungry or thirstier than usual
• hair loss
• changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
• feeling cold
• constipation
• your voice gets deeper
• urinating more often than usual
• nausea or vomiting
• stomach area (abdomen) pain

Problems in other organs. Signs and symptoms may include:
• severe muscle weakness
• numbness or tingling in hands or feet
• confusion
• blurry vision, double vision, or other vision problems
• changes in mood or behavior
• extreme sensitivity to light
• neck stiffness
• eye pain or redness
• skin blisters or peeling
• chest pain, irregular heartbeat, shortness of breath or swelling of the ankles

Severe infections. Signs and symptoms of infection may include:
• fever
• cough
• flu-like symptoms
• pain when urinating, frequent urination or back pain

Severe infusion reactions. Signs and symptoms of infusion reactions may include:
• chills or shaking
• itching or rash
• flushing
• shortness of breath or wheezing
• swelling of your face or lips
• dizziness
• fever
• feeling like passing out
• back or neck pain

Getting medical treatment right away may help keep these problems from becoming more serious.
Your healthcare provider will check you for these problems during your treatment with TECENTRIQ. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may delay or completely stop treatment with TECENTRIQ if you have severe side effects.
What is TECENTRIQ?

TECENTRIQ is a prescription medicine used to treat:

- a type of bladder and urinary tract cancer called urothelial carcinoma. TECENTRIQ may be used when your bladder cancer:
  - has spread or cannot be removed by surgery, and if you have any one of the following conditions:
    - you are not able to take chemotherapy that contains a medicine called cisplatin, and your doctor has tested your cancer and found high levels of a specific protein on your cancer called programmed death-ligand 1 (PD-L1), or
    - you are not able to take chemotherapy that contains any platinum regardless of the levels of PD-L1 on your cancer, or
  - you have tried chemotherapy that contains platinum, and it did not work or is no longer working.

- a type of lung cancer called non-small cell lung cancer (NSCLC). TECENTRIQ may be used when your lung cancer:
  - has spread or grown, and
  - you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
  If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

It is not known if TECENTRIQ is safe and effective in children.

Before you receive TECENTRIQ, tell your healthcare provider about all of your medical conditions, including if you:

- have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
- have had an organ transplant
- have lung or breathing problems
- have liver problems
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
- are being treated for an infection
- are pregnant or plan to become pregnant. TECENTRIQ can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TECENTRIQ.

If you are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with TECENTRIQ.
- You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of TECENTRIQ.

- are breastfeeding or plan to breastfeed. It is not known if TECENTRIQ passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of TECENTRIQ.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive TECENTRIQ?

- Your healthcare provider will give you TECENTRIQ into your vein through an intravenous (IV) line over 30 to 60 minutes.
- TECENTRIQ is usually given every 3 weeks.
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider will test your blood to check you for certain side effects.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What are the possible side effects of TECENTRIQ?

TECENTRIQ can cause serious side effects, including:

See “What is the most important information I should know about TECENTRIQ?”

The most common side effects of TECENTRIQ in people with urothelial carcinoma include:

- feeling tired
- decreased appetite
- nausea
- constipation
- urinary tract infection
- diarrhea
- fever

The most common side effects of TECENTRIQ in people with NSCLC include:

- feeling tired
- decreased appetite
- muscle pain
- cough
- shortness of breath

TECENTRIQ may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of TECENTRIQ. Ask your healthcare provider or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of TECENTRIQ.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you would like more information about TECENTRIQ, talk with your healthcare provider. You can ask your healthcare provider for information about TECENTRIQ that is written for health professionals.

What are the ingredients in TECENTRIQ?

**Active ingredient:** atezolizumab  
**Inactive ingredients:** glacial acetic acid, L-histidine, sucrose, polysorbate 20

Manufactured by Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990 USA

U.S. License No. 1048 TECENTRIQ is a registered trademark of Genentech, Inc.

For more information, call 1-844-832-3687 or go to www.TECENTRIQ.com.

This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 7/2018